Nebula Research & Development LLC Acquires New Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Nebula Research & Development LLC bought a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 18,560 shares of the company's stock, valued at approximately $639,000.

Several other hedge funds have also modified their holdings of HRMY. JPMorgan Chase & Co. increased its stake in shares of Harmony Biosciences by 68.4% in the third quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company's stock worth $9,217,000 after acquiring an additional 93,622 shares during the last quarter. Swiss National Bank grew its position in Harmony Biosciences by 28.2% in the fourth quarter. Swiss National Bank now owns 78,200 shares of the company's stock worth $2,691,000 after acquiring an additional 17,200 shares in the last quarter. Teacher Retirement System of Texas increased its stake in shares of Harmony Biosciences by 50.6% during the 4th quarter. Teacher Retirement System of Texas now owns 11,801 shares of the company's stock worth $406,000 after purchasing an additional 3,964 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Harmony Biosciences by 36.4% during the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after purchasing an additional 1,262,362 shares in the last quarter. Finally, Barclays PLC boosted its holdings in Harmony Biosciences by 110.9% in the third quarter. Barclays PLC now owns 76,862 shares of the company's stock worth $3,074,000 after purchasing an additional 40,416 shares in the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on HRMY shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. Needham & Company LLC reiterated a "buy" rating and set a $50.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 8th. UBS Group decreased their target price on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Monday, April 28th. Finally, Mizuho lifted their price target on Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a report on Tuesday, March 18th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $52.44.

Harmony Biosciences Trading Up 1.5 %

Shares of NASDAQ HRMY traded up $0.46 during mid-day trading on Friday, hitting $30.32. The company's stock had a trading volume of 857,912 shares, compared to its average volume of 574,597. Harmony Biosciences Holdings, Inc. has a one year low of $26.47 and a one year high of $41.61. The company's fifty day simple moving average is $31.41 and its 200-day simple moving average is $34.08. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of 14.37, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.11. The firm had revenue of $201.30 million for the quarter, compared to analysts' expectations of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business's revenue for the quarter was up 19.5% on a year-over-year basis. During the same period last year, the firm earned $0.45 earnings per share. On average, sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.